JEAN-PAUL NUTRACEUTICALS ColloRx Lanosterol Eye Drops 10ml
Lanosterol is the only eye drop on the planet currently that has a real therapeutic effect on cataracts.
Product will be packaged as 10ml with ColloRX (aquatic collagen).
Note: Product may cause transient stinging which last for a couple of seconds.
This is a fragile item and requires refrigeration. Contents should be used within a month of opening and application, and discarded thereafter.
Cataracts affect thousands of dogs around the world and is the leading cause of blindness. Cataracts are formed from cross-linking, a process whereby glycated proteins bind with other proteins and form large insoluble amounts of damaged protein that can accumulate in and disrupt the natural arrangement of the lens crystallin fibres. Factors that contribute to this cross-linking include inflammation, inflammatory cytokines produced in generalized allergies, food sensitivities and environmental factors such as excessive direct UV exposure. Currently the only real solution is surgery as many other earlier therapeutic eye drops (1,2,3,4,5,6) for cataracts has shown only limited success.
Lanosterol has shown to be the only compound implicated as a potential agent to reverse and ‘dissolve’ cataracts in dogs as shown by Zhao et al. in 2015 (7). They discovered mutations in lanosterol synthase (LSS) that contributed to congenital cataracts in three children from a Caucasian family. LSS synthesizes lanosterol which is a naturally occurring steroid in the lens. It is similar to cholesterol. Lanosterol is a tetracyclic triterpenoid and is the compound from which all animal and fungal steroids are derived.
Molecular Formula: C30H50O
It is an amphipathic molecule, i.e. it is both hydrophilic and hydrophobic.
In Zhao’s in vitro study, lens tissues from rabbits were immersed in solution of lanosterol for six days in the dark at room temperature; whilst in the in vivo study, dogs’ eyes received intravitreal injections of lanosterol loaded nanoparticles as well as topical lanosterol drops and the outcomes were measured six weeks later. The degree of cataract assessed by lens clarity before and after the treatment periods was assessed by blinded examiners using an opacification grading system. They found a statistically significant reduction in cataract severity and improvement in lens clarity post-treatment in both studies. They concluded that lanosterol inhibits lens protein aggregation by coating the hydrophobic core areas of large protein aggregates within the lens, thus rendering them water-soluble which improves their clarity.
However currently the implications for human cataract remains unclear Shanmugam et al. in 2015 (8).
adapted from //www.lanomax.com/img/injected-and-administered-with-the-lanosterol-solution.png
DESCRIPTION OF ColloRX® LANOSTEROL EYE DROPS
Addition of collagen –
Collagen when added to the lanosterol, help to stabilize the lanosterol and act as a lubricant to soothe discomfort from dry eye or corneal irritation. It also aids to coat the cornea evenly and increase the contact time of lanosterol with the cornea. This maximizes absorption and lead to less wastage during application
ColloRx® Lanosterol eye drops –
• Lanosterol 10mg
• Aquatic collagen 10% (which act as lubricant and carrier)
• Buffered saline to 10ml in a sterile amber dropper bottle
DIRECTIONS FOR USAGE
Wash hands before use. Shake well (slight flocculation may occur if left standing for too long) before applying one drop to affected eyes 3-4 x a day. Frequency can be reduced to 2 x a day for prophylaxis. Keep refrigerated. Discard any unused portions after 30 days of opening
Avoid any contact of dropper tip with any surface or eye. Discard bottle if any discoloration or large flocculants appear in the solution.
A slight stinging may be experienced by a few patients on initial instillation of the eye drop. This sensation is only transient. If prolonged irritation occurs, this may mean that the patient may have a sensitivity to the drops and it should be discontinued immediately and a health care professional consulted.